Tarsadia Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Tarsadia Capital’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-15,000	Closed	-$1.68M	–	36
2020 Q2	$1.68M	Buy	+15,000	New	+$1.59M	0.3%	28

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tarsadia Capital's ALXN Position: Q3 2020 in Review

Tarsadia Capital sold out of Alexion Pharmaceuticals (ALXN) in Q3 2020, closing a stake of 15,000 shares — an estimated $1.68M sold.

Tarsadia Capital first reported a position in ALXN in Q2 2020 and held it in 1 quarter. The position peaked at $1.68M in Q2 2020. 707 funds tracked by Wall St. Rank hold ALXN as of Q3 2020.

Tarsadia Capital reported no remaining Alexion Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Tarsadia Capital sold 15,000 Alexion Pharmaceuticals shares in Q3 2020, an estimated $1.68M.
Tarsadia Capital first reported a position in Alexion Pharmaceuticals in Q2 2020 and held it in 1 quarter.
Tarsadia Capital's Alexion Pharmaceuticals position peaked at $1.68M in Q2 2020.
707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2020.

Based on Tarsadia Capital's 13F filing for Q3 2020, filed 12 Nov 2020.